SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Hence then, the article about innovent and hutchmed jointly announce nda acceptance in china for sintilimab combination with fruquintinib for the treatment of advanced renal cell carcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma )
Also on site :
- In 1957, Ford launched the Edsel after spending $250 million developing it; two years later Ford discontinued it, having lost $350 million
- In 1948, William Rosenberg used $1,500 in war bonds and a $1,000 loan to open his first coffee shop; Dunkin’ Donuts later sold for $11.3 billion to Inspire Brand
- In 1889, Emile Zatarain began selling root beer from a New Orleans grocery; his family’s spice company sold to McCormick for $180 million in 2003